跳至主要内容
临床试验/NCT06231251
NCT06231251招募中不适用

Impact of Endoscopic Gastric Reduction of Ghrelin Receptors Rich Gastric Mucosa on Obesity and Metabolic Syndrome: a Randomized Controlled Trial

Zagazig University2 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2023年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
48
试验地点
2
主要终点
Number of patients with significant weight reduction

研究概览

简要总结

In the stomach, the ghrelin-containing cells are more abundant in the fundus than in the pylorus originally termed X/A-like cells. These X/A-like cells account for approximately 20 % of the endocrine cell population in adult oxyntic glands.

Ghrelin enhances the secretion of growth hormone, the stimulation of appetite and food intake, the modulation of gastric acid secretion & motility and the endocrine and exocrine pancreatic secretions.

详细描述

Ghrelin is 28 amino acid peptide hormone, approximately 70 % of circulating ghrelin is secreted by the stomach, with most of the remainder originating in duodenum, jejunum, and ileum. Lower amount of secretion outside the gut, including hypothalamus (arcuate nucleus and paraventricular nucleus), pituitary, lung, adrenal cortex, kidney, bone, testis, placenta and pancreatic islet cells Ghrelin enhances the secretion of growth hormone, the stimulation of appetite and food intake, the modulation of gastric acid secretion & motility and the endocrine and exocrine pancreatic secretions. Synthetic ghrelin imitative was shown to increase fat deposition and appetite through an action at the level of the hypothalamus arcuate nucleus mainly the orexigenic neuropeptide Y (NPY) neurons.

Alterations of ghrelin play an important role in appetite fluctuation following meals. The secretion of ghrelin by the stomach depends largely on the nutritional state. Ghrelin levels show pre-prandial increases and postprandial decreases.

Low systemic ghrelin levels have been reported in untreated hyperthyroidism, in male hypogonadism, in the polycystic ovary syndrome, or after total gastrectomy [5, 6].

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • body mass index more than 25
  • diagnosis of diabetes mellitus.
  • diagnosis of cardio-metabolic syndrome.
  • fatty liver disease diagnosed by abdominal ultrasound.

排除标准

  • use of drugs which induce insulin resistance, diabetes and hepatic steatosis.
  • excess alcohol consumption.
  • chronic gastritis, active peptic ulcer.
  • malignancy.
  • depression and severe psychological disorders
  • inability to give informed consent.
  • coagulopathy (INR more than 1.5, platelets less than 50000 per cmm).
  • severe cardiopulmonary comorbidity.

结局指标

主要结局

Number of patients with significant weight reduction

时间窗: 6 month

significant weight reduction of more than 10% of baseline body weight measured in kilograms

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Amr Shaaban Hanafy

professor of medicine and gastroenterology

Zagazig University

研究点 (2)

Loading locations...

相似试验